Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech ( (EVAX) ) just unveiled an announcement.
On October 13, 2025, Evaxion A/S announced that it will present comprehensive data from its phase 2 trial of the AI-designed personalized cancer vaccine, EVX-01, at the ESMO Congress 2025 in Berlin. The presentation will include two-year clinical efficacy, immunogenicity, and safety data, highlighting the vaccine’s potential in treating advanced melanoma. The trial, conducted in combination with Merck’s KEYTRUDA®, has shown promising results, including a 69% overall response rate and significant tumor-specific immune responses. This presentation underscores Evaxion’s innovative approach and strengthens its position in the personalized cancer vaccine sector.
The most recent analyst rating on (EVAX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by its financial challenges, despite strong revenue growth and positive developments in R&D and partnerships. The technical analysis suggests neutral momentum, while valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with financial stability and strategic progress, but regulatory and market challenges remain significant risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company focuses on creating novel immunotherapies for cancer, bacterial diseases, and viral infections through its proprietary AI platform, AI-Immunology™. Evaxion has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical infectious disease pipeline targeting high unmet medical needs.
Average Trading Volume: 1,462,623
Technical Sentiment Signal: Hold
Current Market Cap: $37.27M
For detailed information about EVAX stock, go to TipRanks’ Stock Analysis page.